EAGLE PHARMS INC
EGRX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Income
Balance Sheet
Cash Flow
EGRX Income Statement
EGRX Balance Sheet
EGRX Cash Flow
Recent trades of EGRX by members of U.S. Congress
EGRX Stock Insider Trading Activity
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
EGRX Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
EGRX Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by EGRX's directors and management
Government lobbying spending instances
-
$30,000 Oct 17, 2024 Issue: Medicare/Medicaid Health Issues
-
$30,000 Jul 15, 2024 Issue: Medicare/Medicaid Health Issues
-
$30,000 Apr 17, 2024 Issue: Medicare/Medicaid Health Issues
-
$30,000 Oct 20, 2023 Issue: Medicare/Medicaid Health Issues
-
$30,000 Jul 20, 2023 Issue: Medicare/Medicaid Health Issues
-
$30,000 Apr 17, 2023 Issue: Medicare/Medicaid Health Issues
-
$30,000 Jan 18, 2023 Issue: Medicare/Medicaid Health Issues
-
$30,000 Oct 20, 2022 Issue: Medicare/Medicaid Health Issues
-
$30,000 Jul 20, 2022 Issue: Medicare/Medicaid Health Issues
-
$30,000 Apr 20, 2022 Issue: Medicare/Medicaid Health Issues
-
$30,000 Jan 18, 2022 Issue: Medicare/Medicaid Health Issues
-
$30,000 Oct 23, 2021 Issue: Health Issues Medicare/Medicaid
-
$30,000 Jul 22, 2021 Issue: Health Issues Medicare/Medicaid
-
$40,000 Jul 20, 2021 Issue: Medicare/Medicaid Pharmacy
-
$30,000 Apr 20, 2021 Issue: Health Issues Medicare/Medicaid
-
$60,000 Apr 20, 2021 Issue: Medicare/Medicaid Pharmacy
-
$80,000 Jan 21, 2021 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$30,000 Jan 20, 2021 Issue: Health Issues Medicare/Medicaid
-
$30,000 Oct 20, 2020 Issue: Health Issues Medicare/Medicaid
-
$30,000 Jul 20, 2020 Issue: Health Issues
-
$30,000 Apr 21, 2020 Issue: Health Issues
-
$30,000 Jan 21, 2020 Issue: Health Issues
-
$30,000 Oct 18, 2019 Issue: Health Issues
-
$30,000 Mar 08, 2018 Issue: Health Issues
-
$30,000 Jan 12, 2018 Issue: Health Issues
-
$45,000 Oct 13, 2017 Issue: Health Issues
-
$20,000 Oct 12, 2017 Issue: Health Issues
-
$45,000 Jul 03, 2017 Issue: Health Issues
Estimated quarterly lobbying spending
U.S. Patents
New patents grants
-
Patent Title: Formulations of bendamustine Nov. 12, 2024
-
Patent Title: Pemetrexed formulations Oct. 15, 2024
-
Patent Title: Formulations of bendamustine Jan. 16, 2024
-
Patent Title: Formulations of bendamustine Dec. 19, 2023
-
Patent Title: Pemetrexed formulations Oct. 24, 2023
-
Patent Title: Fulvestrant formulations and methods of their use Feb. 28, 2023
-
Patent Title: Fulvestrant formulations Nov. 23, 2021
-
Patent Title: Formulations of bendamustine Aug. 31, 2021
-
Patent Title: Fulvestrant formulations Jul. 30, 2019
-
Patent Title: Formulations of bendamustine Aug. 21, 2018
-
Patent Title: Formulations of bendamustine Jul. 03, 2018
-
Patent Title: Pharmaceutical compositions containing pemetrexed having extended storage stability May. 23, 2017
-
Patent Title: Formulations of bendamustine Mar. 21, 2017
-
Patent Title: Formulations of bendamustine Mar. 21, 2017
-
Patent Title: Formulations of bendamustine Mar. 21, 2017
-
Patent Title: Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration Feb. 28, 2017
-
Patent Title: Formulations of bendamustine Feb. 21, 2017
-
Patent Title: Formulations of bendamustine Feb. 21, 2017
-
Patent Title: Formulations of bendamustine Feb. 21, 2017
-
Patent Title: Formulations of bendamustine Feb. 21, 2017
-
Patent Title: Formulations of bendamustine Feb. 23, 2016
-
Patent Title: Formulations of bendamustine Sep. 29, 2015
-
Patent Title: Formulations of bendamustine May. 19, 2015
-
Patent Title: Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration Apr. 07, 2015
-
Patent Title: Formulations of bendamustine Dec. 17, 2013
-
Patent Title: Formulations of daptomycin Apr. 30, 2013
-
Patent Title: Vial with collar label Feb. 19, 2013
-
Patent Title: Alcohol free formulation of argatroban Mar. 30, 2010
Government Contracts
Federal grants, loans, and purchases
- $0 2024-01-27 00:00:00 Agency: Department of Veterans Affairs
- $3,003 2022-09-09 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $4,505 2022-08-29 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $4,505 2022-08-29 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $9,010 2022-08-23 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $3,003 2022-05-31 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $1,502 2022-01-31 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $27,029 2022-01-10 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $9,010 2021-12-13 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $4,505 2021-11-17 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $9,010 2021-10-15 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $9,010 2021-09-28 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $9,010 2021-09-28 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $1,502 2021-09-16 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $9,010 2021-09-14 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $15,016 2021-08-24 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $4,505 2021-08-18 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $4,505 2021-08-09 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $9,010 2021-07-28 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $10,511 2021-06-08 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $9,010 2021-05-24 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $6,006 2021-05-20 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $9,010 2021-05-04 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $9,010 2021-04-21 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $12,013 2021-04-12 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $12,013 2021-03-30 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $13,514 2021-03-30 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $4,505 2021-03-30 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $13,514 2021-03-30 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $13,514 2021-03-30 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $9,010 2021-03-30 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $13,514 2021-03-30 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $4,505 2021-03-29 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $12,013 2021-03-29 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $7,508 2021-03-29 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $3,003 2021-03-08 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $9,010 2021-03-01 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $9,010 2021-03-01 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $87,283 2021-03-01 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $3,003 2021-02-18 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $3,003 2021-02-18 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $4,505 2021-02-17 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $4,505 2021-02-16 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $9,010 2021-01-08 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $2,963 2020-11-20 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $4,444 2020-11-20 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $2,963 2020-11-20 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $8,888 2020-11-19 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $8,888 2020-11-19 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $4,444 2020-11-19 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
Government Contracts
Estimated quarterly amount awarded from public contracts
WallStreetBets
Number of mentions of EGRX in WallStreetBets Daily Discussion
EGRX News
Recent insights relating to EGRX
CNBC Recommendations
Recent picks made for EGRX stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in EGRX
EGRX Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view EGRX Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More